Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: cancer + web + 0.22  Related to the article below (Last Update: 8/5/2008)

Incyte Reports Progress in Multiple Clinical Programs; Announces ...
WELT ONLINE, Germany - Jul 29, 2008
Sheddase Inhibitor Program INCB7839: Breast Cancer -- Continued to enroll patients in a Phase II trial in combination with Herceptin(R) with top-line ...INCY
From trans fats to chemicals, public perceptions of health risks ...
guardian.co.uk, UK - Jul 11, 2008
Yet because we only learned of acrylamide's existence in foods recently, and because very large amounts fed to animals cause cancer, there have been calls ...
Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 ...
PR Newswire (press release), NY - 14 minutes ago
Revenue from Endu, the Company's patented anti-cancer pharmaceutical launched in July 2006, totaled RMB63.1 million (US$9.2 million) in the second quarter ...SCR
Blackbaud, Inc. Announces Second Quarter 2008 Results and Third ...
TMC Net, CT -
Approximately 22000 organizations -- including University of Arizona Foundation, American Red Cross, Cancer Research UK, The Taft School, Lincoln Center, ...BLKB
Progress Energy Increases 2008 Production Guidance
istockAnalyst.com, OR - Jul 31, 2008
Mr. Fred Coles passed away after a long and courageous battle with cancer. He was a member of Progress' Board since inception and contributed his wealth of ...TSE:PGX.UN
IRIS Reports Record Second Quarter Revenues, Profit and EPS, and ...
Genetic Engineering News (press release), NY - Jul 28, 2008
IRIS will submit a new 510(k) seeking clearance of a prognostic claim for identifying post-prostatectomy patients with low-risk of prostate cancer ...IRIS
Source: Google News

Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy … -
EK Ng, NB Tsui, NY Lam, RW Chiu, SC Yu, SC Wong, … - Clin Chem, 2002 - Am Assoc Clin Chem
... Presence of Filterable and Nonfilterable mRNA in the Plasma of Cancer Patients and ...
through filters with different pore sizes (from 5 ?m to 0.22 ?m) and ...

Risk of head and neck cancer and the alcohol dehydrogenase 3 genotype -
AF Olshan - Carcinogenesis, 2001 - Oxford Univ Press
... number of drinks per week and the ADH3 genotypes, was non-significant (P = 0.22). ...
K Horrmann, S Vakevainen, M Salaspuro, and HK Seitz Increased cancer risk in ...

… throughout life and risk of breast cancer: the Western New York Exposures and Breast Cancer (WEB) … -
J Nie, J Beyea, MR Bonner, D Han, JE Vena, P … - Cancer Causes and Control, 2007 - Springer
... p for trend 0.32 0.22 ... Table 4 Exposure to traffic emissions throughout life and
risk of breast cancer by smoking status, WEB Study, 1996?2001 ...

Cancer CAMTM: Web-Based Continuing Education for Health Professionals
SG Brink, AE McFarren, JM Lincoln, AJ Birney - Complementary Health Practice Review, 2004 - chp.sagepub.com
... with physicians about why prostate cancer patients use ... diet showed little change
(mean difference = 0.22, df = 40 ... Key Points,??References,?and Web links a ...

Primary care clinicians' performance for detecting actinic keratoses and skin cancer -
JD Whited, RP Hall, DL Simel, RD Horner - Archives of Internal Medicine, 1997 - Am Med Assoc
... your Web browser does not support basic Web standards ... BACKGROUND: If skin cancer
screening is to become ... 0.36; 95% confidence interval [CI], 0.22-0.50), multiple ...

Cancer Statistics, 2007 -
A Jemal, R Siegel, E Ward, T Murray, J Xu, MJ Thun - CA: A Cancer Journal for Clinicians, 2007 - Am Cancer Soc
... Michael Cancer Statistics, 2007 This information is current as of January 30, 2007
http://caonline.amcancersoc.org/cgi/content/full/57/1/43 the World Wide Web ...

… and Twinning Rates as Measures of Fertility Before Diagnosis of Germ-Cell Testicular Cancer -
L Richiardi, O Akre, SM Montgomery, M Lambe, U … - jnci, 2004 - jnci.oxfordjournals.org
... with no children), with a lower frequency of dizygotic twinning (for unlike-sex
twins, OR for the father having testicular cancer = 0.49, 95% CI = 0.22 to 1.08 ...

… Oxidative Stress in the Association of Hormone Replacement Therapy with Postmenopausal Breast Cancer …
SK Quick, PG Shields, J Nie, ME Platek, SE McCann, … - Cancer Epidemiology Biomarkers & Prevention, 2008 - AACR
... and non-Whites (n = 97 CC, 10 CT, and 1 TT; P = 0.22). ... and postmenopausal breast
cancer, Western New York Exposures and Breast Cancer Study (WEB Study). ...
-

Serum a-Tocopherol and ?-Tocopherol in Relation to Prostate Cancer Risk in a Prospective Study -
SJ Weinstein, ME Wright, P Pietinen, I King, C Tan … - jnci, 2005 - jnci.oxfordjournals.org
... cholesterol (r = 0.61 and 0.22). View this table: [in this window] [in a new window],
Table 1. Selected baseline characteristics of prostate cancer patients and ...

[PDF] A gene expression database for the molecular pharmacology of cancer -
U Scherf, DT Ross, M Waltham, LH Smith, JK Lee, L … - Nat Genet, 2000 - embnet.cl
... laboratories, as compiled at the DTP web site (http ... from a pleural effusion of a
patient with breast cancer. ... A6 carmustine (BCNU) 409962 4.15 0.22 136 42.5 Db ...
-

Source: Google Scholar

Impact Of Taking Cancer Drug With Food Highlighted By Commentary
A commentary in the Journal of Clinical Oncology (JCO) urges researchers to explore an intriguing approach to reduce the dose, and therefore the cost, of oral targeted cancer therapies. The commentary, by Mark Ratain, MD and Ezra Cohen, MD of the University of Chicago, examines recent pharmacologic research which found that taking the targeted therapy lapatinib (Tykerb) with food significantly increased the concentration of the drug in the body. The commentary suggests that taking lapatinib with food instead of on an empty stomach, as currently indicated, could cut the needed dose by at least 60 percent, reducing the cost accordingly. The authors stress that formal studies are needed to determine the effectiveness of this approach. The article is published in the Journal of Clinical Oncology.
The commentary focuses on a study presented at the March 2007 meeting of the American Society for Clinical Pharmacology and Therapeutics, which found that lapatinib is more readily absorbed by the body when taken with food, particularly a high-fat meal. As a result, 500 mg of lapatinib taken with food may be as effective as taking the currently approved 1,250 mg without food.

Lapatinib was approved by the U.S. Food and Drug Administration (FDA) in March of this year for women with advanced HER2-positive breast cancer. The FDA approved the 1,250 mg dose of lapatinib based on a large phase III clinical trial demonstrating its effectiveness and safety at that dose without food. It is taken as five 250 mg tablets on an empty stomach and costs $2,900 per month.

The cost of new targeted cancer therapies -- which can be as high as $10,000 per month -- has generated substantial discussion and debate. "The economic implications of this food effect study are particularly remarkable. At the current price of $2,900 per month, this would have a cost savings of 60 percent or $1,740 per month" the commentary states. "As we enter an era of 'targeted' anticancer agents with a monthly cost measured in the thousands of dollars, we should view drug-drug or drug-food interactions as opportunities to lower costs."

The commentary states that rising cancer drug prices are encouraging researchers to explore such pharmacologic approaches to lowering costs. However, the authors urge that neither physicians nor patients consider changing lapatinib dose based on these findings, and that everyone strictly follow the prescribing label directions, which are based on the findings of rigorous clinical tests. The authors strongly emphasize that a formal pharmacokinetic study of a lower dose of lapatinib with food would need to confirm these findings before any change in dosage could be considered safe and effective.

"The Value Meal: How to Save $1,700 Per Month or More on Lapatinib." Mark J. Ratain, MD and Ezra E. Cohen, MD, University of Chicago, Chicago, IL.
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians of all oncology subspecialties who care for people with cancer. ASCO's nearly 25,000 members from the United States and abroad set the standard for patient care and lead the efforts to discover more effective cancer treatments, increase funding for clinical and translational research, and, ultimately, improve cancer care for the estimated 10 million people diagnosed with cancer worldwide each year. ASCO publishes the Journal of Clinical Oncology (JCO), the preeminent, peer-reviewed, medical journal on clinical cancer research, and produces People Living With Cancer (http://www.plwc.org/), a comprehensive consumer website providing oncologist-vetted cancer information to help patients and families make informed health-care decisions.

Source: Tiffany Reynolds
American Society of Clinical Oncology
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
ALL THE NEWS : News1 ; News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.